Jula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 815 shares of Travere Therapeutics stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $14.65, for a total transaction of $11,939.75. Following the transaction, the insider owned 88,787 shares in the company, valued at $1,300,729.55. The trade was a 0.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Travere Therapeutics Price Performance

Travere Therapeutics stock traded up $0.16 during trading hours on Friday, hitting $15.00. 663,493 shares of the company traded hands, compared to its average volume of 1,621,333. Travere Therapeutics, Inc. has a 1-year low of $7.93 and a 1-year high of $25.29. The firm has a market cap of $1.33 billion, a P/E ratio of -5.34 and a beta of 0.72. The firm's 50-day simple moving average is $16.72 and its two-hundred day simple moving average is $18.14. The company has a quick ratio of 2.03, a current ratio of 2.05 and a debt-to-equity ratio of 9.46.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The business had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same period last year, the firm posted ($1.76) earnings per share. The business's revenue was up 83.3% on a year-over-year basis. As a group, analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday, April 23rd. Bank of America lifted their target price on Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Travere Therapeutics in a research report on Tuesday. Guggenheim reissued a "buy" rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Monday, April 14th. Finally, Citigroup lowered their price objective on Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $32.14.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $31,000. Sterling Capital Management LLC grew its position in Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after buying an additional 2,115 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Travere Therapeutics in the first quarter valued at $62,000. KBC Group NV acquired a new stake in shares of Travere Therapeutics during the 1st quarter valued at $75,000. Finally, Gen Wealth Partners Inc acquired a new stake in shares of Travere Therapeutics during the 4th quarter valued at $73,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.